Literature DB >> 22881387

Effects of tuberculosis on the kinetics of CD4(+) T cell count among HIV-infected patients who initiated antiretroviral therapy early after tuberculosis treatment.

Nam Su Ku1, Jin Ok Oh, So Youn Shin, Sun Bean Kim, Hye-won Kim, Su Jin Jeong, Sang Hoon Han, Young Goo Song, June Myung Kim, Jun Yong Choi.   

Abstract

The effects of tuberculosis (TB) on the kinetics of CD4(+) T cells among HIV-infected individuals with early combination antiretroviral therapy (cART) after TB therapy initiation are poorly characterized. We conducted a case-control study with 15 HIV-TB-coinfected patients who initiated TB treatment and early cART, and 30 controls without TB who had similar CD4(+) T cell counts and viral loads at the time of starting cART. We compared the rate of CD4(+) T cell increase for 5 years after cART. The time to CD4(+) T cell increase >250 cells/mm(3) was significantly slower in HIV-TB-coinfected patients (p=0.015, by log rank test). HIV-TB-coinfected patients had significantly lower median CD4(+) T cell counts at 5 years after cART (p=0.048). The difference in CD4(+) T cell increase was observed only during the first 6 months after cART initiation (p=0.002). These data suggest that TB slows the rate of CD4(+) T cell recovery at an early period after cART. The effects of TB on the long-term immunity of HIV-infected patients should be further evaluated.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22881387      PMCID: PMC3552174          DOI: 10.1089/AID.2012.0192

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  28 in total

Review 1.  Initial highly-active antiretroviral therapy with a protease inhibitor versus a non-nucleoside reverse transcriptase inhibitor: discrepancies between direct and indirect meta-analyses.

Authors:  Roger Chou; Rongwei Fu; Laurie Hoyt Huffman; P Todd Korthuis
Journal:  Lancet       Date:  2006-10-28       Impact factor: 79.321

2.  Antiretroviral treatment regimen outcomes among HIV-infected prisoners.

Authors:  Sandra A Springer; Gerald H Friedland; Gheorghe Doros; Edward Pesanti; Frederick L Altice
Journal:  HIV Clin Trials       Date:  2007 Jul-Aug

Review 3.  The absence of CD4+ T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy: clinical risk, immunological gaps, and therapeutic options.

Authors:  Lidia Gazzola; Camilla Tincati; Giusi Maria Bellistrì; Antonella d'Arminio Monforte; Giulia Marchetti
Journal:  Clin Infect Dis       Date:  2009-02-01       Impact factor: 9.079

4.  A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial.

Authors:  Rodger D MacArthur; Richard M Novak; Grace Peng; Li Chen; Ying Xiang; Katherine Huppler Hullsiek; Michael J Kozal; Mary van den Berg-Wolf; Christopher Henely; Barry Schmetter; Marjorie Dehlinger
Journal:  Lancet       Date:  2006-12-16       Impact factor: 79.321

Review 5.  Towards universal access to HIV prevention, treatment, care, and support: the role of tuberculosis/HIV collaboration.

Authors:  Alasdair Reid; Fabio Scano; Haileyesus Getahun; Brian Williams; Christopher Dye; Paul Nunn; Kevin M De Cock; Catherine Hankins; Bess Miller; Kenneth G Castro; Mario C Raviglione
Journal:  Lancet Infect Dis       Date:  2006-08       Impact factor: 25.071

6.  Comparative analysis of T-cell turnover and homeostatic parameters in HIV-infected patients with discordant immune-virological responses to HAART.

Authors:  Giulia Marchetti; Andrea Gori; Anna Casabianca; Mauro Magnani; Fabio Franzetti; Mario Clerici; Carlo-Federico Perno; Antonella d'Arminio Monforte; Massimo Galli; Luca Meroni
Journal:  AIDS       Date:  2006-08-22       Impact factor: 4.177

7.  Timing of initiation of antiretroviral drugs during tuberculosis therapy.

Authors:  Salim S Abdool Karim; Kogieleum Naidoo; Anneke Grobler; Nesri Padayatchi; Cheryl Baxter; Andrew Gray; Tanuja Gengiah; Gonasagrie Nair; Sheila Bamber; Aarthi Singh; Munira Khan; Jacqueline Pienaar; Wafaa El-Sadr; Gerald Friedland; Quarraisha Abdool Karim
Journal:  N Engl J Med       Date:  2010-02-25       Impact factor: 91.245

8.  Incident tuberculosis during antiretroviral therapy contributes to suboptimal immune reconstitution in a large urban HIV clinic in sub-Saharan Africa.

Authors:  Sabine M Hermans; Agnes N Kiragga; Petra Schaefer; Andrew Kambugu; Andy I M Hoepelman; Yukari C Manabe
Journal:  PLoS One       Date:  2010-05-07       Impact factor: 3.240

9.  Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis.

Authors:  Catherine Boulanger; Elena Hollender; Karen Farrell; Jerry Jean Stambaugh; Diane Maasen; David Ashkin; Stephen Symes; Luis A Espinoza; Rafael O Rivero; Jenny J Graham; Charles A Peloquin
Journal:  Clin Infect Dis       Date:  2009-11-01       Impact factor: 9.079

10.  Effect of tuberculosis on the survival of HIV-infected men in a country with low tuberculosis incidence.

Authors:  Hugo López-Gatell; Stephen R Cole; Joseph B Margolick; Mallory D Witt; Jeremy Martinson; John P Phair; Lisa P Jacobson
Journal:  AIDS       Date:  2008-09-12       Impact factor: 4.177

View more
  1 in total

Review 1.  Understanding the Relationship between Glutathione, TGF-β, and Vitamin D in Combating Mycobacterium tuberculosis Infections.

Authors:  Mohkam Singh; Charles Vaughn; Kayvan Sasaninia; Christopher Yeh; Devanshi Mehta; Ibrahim Khieran; Vishwanath Venketaraman
Journal:  J Clin Med       Date:  2020-08-26       Impact factor: 4.241

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.